April 2024 OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
April 2024 OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
March 2024 OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
March 2024 OSE Immunotherapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis
February 2024 OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership On February 28, 2024, at 6:00 p.m. CET / 12:00 a.m. ET.
February 2024 AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
February 2024 OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors
January 2024 OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook
December 2023 OSE Immunotherapeutics and Nantes University Hospital Present Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
November 2023 OSE Immunotherapeutics Announces a Collaboration Agreement with GenDx for the Development of a Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi®